Advertisement
Screener

ASTRAZENECA PLC (AZN) Form 6-K: Report of foreign private issuer, 2019

2.4 / 5 stars · 19/40 Roast Me

Add as a preferred source on Google

ASTRAZENECA PLC Form 6-K: Report of foreign private issuer

Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.

  • 2019-12-30: Form 6-K; Period of report 2019-12-30; Description LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-; Document a2293y.htm.
  • 2019-12-23: Form 6-K; Period of report 2019-12-23; Description ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COP; Document a7906x.htm.
  • 2019-12-23: Form 6-K; Period of report 2019-12-23; Description ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTAB; Document a7470x.htm.
  • 2019-12-20: Form 6-K; Period of report 2019-12-20; Description ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIO; Document a6174x.htm.
FiledFormPeriod of reportDescriptionDocument
2019-12-306-K2019-12-30LYNPARZAAPPROVED IN THE US AS A 1ST-LINE MAINTENANCE TREATMENT OF GERMLINE BRCA-a2293y.htm
2019-12-236-K2019-12-23ASTRAZENECA'S TRIPLE-COMBINATION THERAPY APPROVED IN CHINA FOR PATIENTS WITH COPa7906x.htm
2019-12-236-K2019-12-23ENHERTU (TRASTUZUMAB DERUXTECAN) APPROVED IN THE US FOR HER2-POSITIVE UNRESECTABa7470x.htm
2019-12-206-K2019-12-20ASTRAZENECA DIVESTS RIGHTS TO ARIMIDEX AND CASODEX IN EUROPE AND CERTAIN ADDITIOa6174x.htm
2019-12-176-K2019-12-17FDA PANEL BACKS LYNPARZA USE FOR PANCREATIC CANCERa2338x.htm
2019-12-166-K2019-12-16SEROQUEL RIGHTS AGREEMENT COMPLETE: EUROPE, RUSSIAa9508w.htm
2019-12-126-K2019-12-12IMFINZI APPROVED IN CHINA FOR THE TREATMENT OF UNRESECTABLE, STAGE III NON-SMALLa6397w.htm
2019-12-116-K2019-12-11TRASTUZUMAB DERUXTECAN ACHIEVED A TUMOUR RESPONSE RATE OF 60.9% IN PIVOTAL PHASEa5495w.htm
2019-12-056-K2019-12-05LYNPARZA APPROVED IN CHINA AS A 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVa7885v.htm
2019-12-036-K2019-12-03ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN THE US AND CANADAa4614v.htm
2019-12-026-K2019-12-02BLOCK LISTING INTERIM REVIEWa3789v.htm
2019-12-026-K2019-12-02TOTAL VOTING RIGHTSa3783v.htm
2019-11-296-K2019-11-29IMFINZI GRANTED FDA PRIORITY REVIEW FOR THE TREATMENT OF PATIENTS WITH EXTENSIVEa1180v.htm
2019-11-216-K2019-11-21CALQUENCE APPROVED IN THE US FOR ADULT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMa2857u.htm
2019-11-156-K2019-11-15QTRILMET APPROVED IN THE EU FOR TREATMENT OF T2Da5478t.htm
2019-11-146-K2019-11-14FDA ACCEPTS REGULATORY SUBMISSION FOR SELUMETINIBa3493t.htm
2019-11-126-K2019-11-12ANIFROLUMAB DEMONSTRATED SUPERIORITY ACROSS MULTIPLE EFFICACY ENDPOINTS IN PATIEa0413t.htm
2019-11-126-K2019-11-12ROXADUSTAT PHASE III PROGRAMME POOLED ANALYSES SHOWED POSITIVE EFFICACY AND NO Ia8848s.htm
2019-11-086-K2019-11-08ROXADUSTAT SIGNIFICANTLY INCREASED HAEMOGLOBIN LEVELS FOR CHRONIC KIDNEY DISEASEa7223s.htm
2019-11-066-K2019-11-06CALQUENCE DATA TO SHOW IMPROVED PROGRESSION-FREE SURVIVAL IN PHASE III FRONT-LINa5211s.htm
2019-11-016-K2019-11-01TOTAL VOTING RIGHTSa0101s.htm
2019-10-306-K2019-10-30ASTRAZENECA DIVESTS RIGHTS TO SEROQUEL AND SEROQUEL XR IN EUROPE AND RUSSIAa5423r.htm
2019-10-286-K2019-10-28IMFINZI AND IMFINZI PLUS TREMELIMUMAB DELAYEDa3764r.htm
2019-10-246-K2019-10-24ASTRAZENECA YEAR-TO-DATE AND Q3 2019 RESULTSa9391q1.htm
2019-10-216-K2019-10-21FARXIGA APPROVED IN THE US TO REDUCE THE RISK OF HOSPITALISATION FOR HEART FAILUa5066q.htm
2019-10-176-K2019-10-17TRASTUZUMAB DERUXTECAN GRANTED FDA PRIORITY REVIEW FOR TREATMENT OF PATIENTS WITa1966q.htm
2019-10-046-K2019-10-04HOLDING(S) IN COMPANYa8426o.htm
2019-10-046-K2019-10-04HOLDING(S) IN COMPANYa8418o.htm
2019-10-046-K2019-10-04FASENRA APPROVED IN THE US FOR SELF-ADMINISTRATIONa7461o.htm
2019-10-036-K2019-10-03DIRECTOR DECLARATIONa7246o.htm
2019-10-016-K2019-10-01TOTAL VOTING RIGHTSa3605o.htm
2019-10-016-K2019-10-01ASTRAZENECA DIVESTS RIGHTS FOR LOSEC TO CHEPLAPHARa2878o.htm
2019-10-016-K2019-10-01UPDATE ON US REGULATORY REVIEW OF PT010 IN COPDa2875o.htm
2019-09-306-K2019-09-30LYNPARZA MORE THAN DOUBLED THE TIME WITHOUT RADIOGRAPHIC DISEASE PROGRESSION IN a1899o.htm
2019-09-306-K2019-09-30LYNPARZA IMPROVED THE TIME WOMEN LIVED WITHOUT DISEASE PROGRESSION TO 22 MONTHS a0558o.htm
2019-09-306-K2019-09-30TAGRISSO IS THE ONLY 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CELL LUNG CANa0560o.htm
2019-09-236-K2019-09-23QTRILMET RECOMMENDED FOR APPROVAL IN EU BY CHMPa2444n.htm
2019-09-186-K2019-09-18ASTRAZENECA AMENDS COLLABORATION WITH IRONWOOD FOR LINZESS IN CHINAa7651m.htm
2019-09-096-K2019-09-09IMFINZI IS FIRST IMMUNOTHERAPY TO SHOW BOTH SIGNIFICANT SURVIVAL BENEFIT AND IMPa5839l.htm
2019-09-046-K2019-09-04TAGRISSO APPROVED IN CHINA AS A 1ST-LINE TREATMENT FOR EGFR-MUTATED NON-SMALL CEa1625l.htm
2019-09-036-K2019-09-03TOTAL VOTING RIGHTSa9231k.htm
2019-09-036-K2019-09-03DETAILED RESULTS FROM PHASE III DAPA-HF TRIAL SHOWED FARXIGA SIGNIFICANTLY REDUCa8036k.htm
2019-09-036-K2019-09-03BRILINTA REDUCED THE RISK OF CARDIOVASCULAR EVENTS IN PATIENTS WITH CORONARY ARTa8034k.htm
2019-08-296-K2019-08-29ANIFROLUMAB PHASE III TRIAL MEETS PRIMARY ENDPOINT IN SYSTEMIC LUPUS ERYTHEMATOSa5256k.htm
2019-08-286-K2019-08-28BREZTRI AEROSPHERE PHASE III ETHOS TRIAL MET ITS PRIMARY ENDPOINT IN CHRONIC OBSa3736k.htm
2019-08-286-K2019-08-28FASENRA GRANTED US ORPHAN DRUG DESIGNATION FOR EOSINOPHILIC OESOPHAGITISa3732k.htm
2019-08-226-K2019-08-22ROXADUSTAT APPROVED IN CHINA FOR THE TREATMENT OF ANAEMIA IN NON-DIALYSIS-DEPENDa8929j.htm
2019-08-226-K2019-08-22ASTRAZENECA AGREES TO BUY US FDA PRIORITY REVIEWa8505j.htm
2019-08-216-K2019-08-21UPDATE ON THE PHASE III NEPTUNE TRIALa7016j.htm
2019-08-206-K2019-08-20FARXIGA MET PRIMARY ENDPOINT IN LANDMARK PHASE IIIa5997j.htm
2019-08-196-K2019-08-19DIRECTORATE CHANGEa4118j.htm
2019-08-146-K2019-08-14CALQUENCE GRANTED US BREAKTHROUGH THERAPY DESIGNATIONa9925i.htm
2019-08-146-K2019-08-14LYNPARZA PHASE III PAOLA-1 TRIAL MET PRIMARY ENDPOINTa9933i.htm
2019-08-096-K2019-08-09TAGRISSO SIGNIFICANTLY IMPROVES OVERALL SURVIVALa5535iamendment.htm
2019-08-076-K2019-08-07LYNPARZA PHASE III PROFOUND TRIAL IN HRR*a2083i.htm
2019-08-056-K2019-08-05FORXIGA LABEL UPDATED IN THE EU IN TYPE-2 DIABETESa8660h.htm
2019-08-016-K2019-08-01TOTAL VOTING RIGHTSa6173h.htm
2019-07-256-K2019-06-306-Ka19-12893_16k.htm
2019-07-156-K2019-07-15UPDATE ON US REGULATORY DECISION FOR FARXIGAa4976f.htm
2019-07-126-K2019-07-12IMFINZI GRANTED US ORPHAN DRUG DESIGNATION FOR SMALL CELL LUNG CANCERa3075f.htm
2019-07-016-K2019-07-01FASENRA RECEIVES POSITIVE EU CHMP OPINION FOR SELFa9357d.htm
2019-07-016-K2019-07-01TOTAL VOTING RIGHTSa0712e.htm
2019-07-016-K2019-07-01FORXIGA RECEIVES POSITIVE EU CHMP OPINION FORa9327d.htm
2019-06-276-K2019-06-27IMFINZI IMPROVES OVERALL SURVIVAL AT INTERIMa5770d.htm
2019-06-196-K2019-06-19BREZTRI AEROSPHERE (PT010) APPROVED IN JAPAN FOR PATIENTS WITH CHRONIC OBSTRUCTIa7213c.htm
2019-06-196-K2019-06-19LYNPARZA APPROVED IN JAPAN FOR 1ST-LINE MAINTENANCE THERAPY IN BRCA-MUTATED ADVAa6835c.htm
2019-06-196-K2019-06-19BEVESPI AEROSPHERE APPROVED BY THE JAPANESE MINISTRY OF HEALTH, LABOUR AND WELFAa6830c.htm
2019-06-186-K2019-06-18LYNPARZA APPROVED IN THE EU FOR 1ST-LINEa5409c.htm
2019-06-176-K2019-06-17CALQUENCE SIGNIFICANTLY PROLONGED THE TIME PATIENTa4354c.htm
2019-06-126-K2019-06-12PUBLICATION OF A PROSPECTUSa0178c.htm
2019-06-066-K2019-06-06CALQUENCE PHASE III ELEVATE-TN TRIAL MET PRIMARYa3503b.htm
2019-06-036-K2019-06-03BLOCK LISTING INTERIM REVIEWa8394a.htm
2019-06-036-K2019-06-03TOTAL VOTING RIGHTSa8390a.htm
2019-06-036-K2019-06-03LYNPARZA NEARLY DOUBLED THE TIME PATIENTS LIVED WITHOUT DISEASE PROGRESSION FROMa8506a.htm
2019-05-106-K2019-05-10POOLED ANALYSES OF THE ROXADUSTAT GLOBAL PHASE IIIa6305y.htm
2019-05-086-K2019-05-08DIRECTOR/PDMR SHAREHOLDINGa3968y.htm
2019-05-086-K2019-05-08DIRECTOR DECLARATIONa3755y.htm
2019-05-086-K2019-05-08TRASTUZUMAB DERUXTECAN DEMONSTRATED CLINICALLYa2933y.htm
2019-05-076-K2019-05-07CALQUENCE PHIII ASCEND TRIAL MET PRIMARY ENDPOINTa1215y.htm
2019-05-036-K2019-05-03QTERNMET XR APPROVED IN THE US FOR TYPE-2 DIABETESa9638x.htm
2019-05-016-K2019-05-01TOTAL VOTING RIGHTSa7776x.htm
2019-05-016-K2019-05-01DIRECTOR/PDMR SHAREHOLDINGa7562x.htm
2019-04-296-K2019-04-29LYNPARZA RECEIVES POSITIVE EU CHMP OPINION FOR 1STa3645x.htm
2019-04-266-K2019-04-26RESULT OF AGMa3125x.htm
2019-04-266-K2019-04-26AZN: Q1 2019 RESULTSa1704x.htm
2019-04-106-K2019-04-10LYNPARZA APPROVED IN EU FOR THE TREATMENT OF GERMLINE BRCA-MUTATED HER2-NEGATIVEa6871v.htm
2019-04-046-K2019-04-04HOLDING(S) IN COMPANYa1694v.htm
2019-04-036-K2019-04-03DIRECTOR/PDMR SHAREHOLDINGa9874u.htm
2019-04-026-K2019-04-02TOTAL VOTING RIGHTSa8735u.htm
2019-04-016-K2019-04-01TOTAL VOTING RIGHTSa7148u.htm
2019-04-016-K2019-04-01SELUMETINIB GETS BREAKTHROUGH THERAPY DESIGNATIONa5844u.htm
2019-03-296-K2019-03-29RESULTS OF PLACINGa5642u.htm
2019-03-296-K2019-03-29AZ AND DAIICHI SANKYO ENTER COLLABORATION IN NOVELa4052u.htm
2019-03-276-K2019-03-27FORXIGA APPROVED IN JAPAN FOR TYPE-1 DIABETESa1400u.htm
2019-03-256-K2019-03-25FORXIGA APPROVED IN EUROPE FOR TYPE-1 DIABETESa8484t.htm
2019-03-186-K2019-03-18US FDA GRANTS SARACATINIB ODD FOR IPFa0968t.htm
2019-03-146-K2019-03-14NOTICE OF AGMa8978s.htm
2019-03-146-K2019-03-146-Ka19-3601_46k.htm
2019-03-126-K2019-03-12DIRECTOR/PDMR SHAREHOLDINGa5989s.htm
2019-03-066-K2019-03-06FILING OF FORM 20-F WITH SECa9502r.htm
Advertisement